SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENT MARKET ANALYSIS
Regional dynamics
North America is expected to be the dominant market in the global SLE treatment market, over the forecast period. This is owing to relatively higher prevalence of SLE in this region as compared to other regions. According to study published in the Rheumatology Journal, in May 2017, incidence and prevalence of SLE in North America was 23.2 people per 1, 00,000 and 241 per 1, 00,000 people, respectively. High presence of market players in North America is also another factor for growth of the market in this region. Key players such as GlaxoSmithKline, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb in systemic lupus erythematosus market have high presence in this region.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
